FDA Eases Access to Peptides as Former Officials Warn of Risks to Drug Approval
Updated
Updated · Scripps News · Jun 30
FDA Eases Access to Peptides as Former Officials Warn of Risks to Drug Approval
1 articles · Updated · Scripps News · Jun 30
Summary
The FDA is moving to make peptides easier to obtain, even as former agency officials warn the shift could weaken the U.S. drug-approval process.
Peptides are short chains of amino acids that act as biological messengers, and some established medicines — including insulin and GLP-1 drugs such as semaglutide and tirzepatide — are peptide-based.
The concern centers on many newer compounds sold in vials marked "for research only," meaning they are not approved for human use despite growing health and beauty marketing.
Dr. Omar Awan said the evidence varies sharply: FDA-approved peptides have gone through rigorous clinical trials, while many products promoted on social media rely on limited animal, lab or small human studies.